Constellation Brands, Levi Strauss And 3 Stocks To Watch Heading Into Thursday
Portfolio Pulse from Avi Kapoor
U.S. stock futures are trading lower, with Constellation Brands, Levi Strauss, AngioDynamics, BigCommerce, and Processa Pharmaceuticals in focus. Constellation Brands is expected to report earnings, Levi Strauss posted mixed results, AngioDynamics is expected to post a loss, BigCommerce appointed a new CEO, and Processa Pharmaceuticals announced a Phase 2 trial.
October 03, 2024 | 7:10 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Levi Strauss reported better-than-expected earnings but missed sales estimates. FY 2024 earnings guidance midpoint is below estimates. Shares fell 10.9% after-hours.
The mixed earnings report and lower-than-expected guidance led to a significant drop in share price, indicating a negative short-term impact.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90
NEUTRAL IMPACT
Constellation Brands is expected to report earnings of $4.08 per share on $2.90 billion revenue. Shares fell 0.3% in after-hours trading.
The earnings report is a significant event for Constellation Brands, but the slight dip in after-hours trading suggests neutral short-term impact unless earnings deviate significantly from expectations.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
AngioDynamics is expected to post a loss of 15 cents per share on $67.93 million revenue. Shares gained 2.1% after-hours.
Despite the expected loss, the positive after-hours movement suggests investor optimism, possibly due to other factors not detailed in the article.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
BigCommerce appointed Travis Hess as CEO, replacing Brent Bellm. Shares rose 1.4% after-hours.
The leadership change is seen positively by the market, as indicated by the share price increase, suggesting a positive short-term impact.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Processa Pharmaceuticals announced the dosing of its first patient in a Phase 2 trial. Shares surged 3% after-hours.
The initiation of a Phase 2 trial is a positive development, leading to a rise in share price, indicating a positive short-term impact.
CONFIDENCE 75
IMPORTANCE 40
RELEVANCE 50